0000950170-24-024970.txt : 20240304
0000950170-24-024970.hdr.sgml : 20240304
20240304172540
ACCESSION NUMBER: 0000950170-24-024970
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burgess Justin
CENTRAL INDEX KEY: 0001812025
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34207
FILM NUMBER: 24716101
MAIL ADDRESS:
STREET 1: C/O DYNAVAX TECHNOLOGIES CORPORATION
STREET 2: 2100 POWELL STREET, SUITE 1900
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001029142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330728374
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5108485100
MAIL ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
4
1
ownership.xml
4
X0508
4
2024-03-01
0001029142
DYNAVAX TECHNOLOGIES CORP
DVAX
0001812025
Burgess Justin
C/O DYNAVAX TECHNOLOGIES
2100 POWELL STREET, SUITE 720
EMERYVILLE
CA
94608
false
true
false
false
Chief Accounting Officer
false
Common Stock
2024-03-01
4
M
false
4334
11.12
A
17759
D
Common Stock
2024-03-01
4
M
false
2767
9.41
A
20526
D
Common Stock
2024-03-01
4
S
false
7101
12.78
D
13425
D
Common Stock
2024-03-01
4
S
false
13425
12.78
D
0
D
Stock Options (Right to Buy)
11.12
2024-03-01
4
M
false
4334
0
D
2030-02-15
Common Stock
0
8666
D
StockOptions (Right to Buy)
9.41
2024-03-01
4
M
false
2767
0
D
2028-02-02
Common Stock
0
0
D
Code M - Exercise or conversion of derivative security
Code S - Open market or private sale of non-derivative or derivative security
This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
/s/ JUSTIN BURGESS
2024-03-04